C WorldWide Group Holding A S reduced its position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 7.6% during the second quarter, Holdings Channel reports. The firm owned 10,793 shares of the biopharmaceutical company’s stock after selling 884 shares during the period. C WorldWide Group Holding A S’s holdings in Lexicon Pharmaceuticals were worth $178,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in LXRX. Highbridge Capital Management LLC purchased a new stake in Lexicon Pharmaceuticals during the first quarter worth $7,813,000. Sector Gamma AS purchased a new stake in Lexicon Pharmaceuticals during the first quarter worth $4,765,000. Wellington Management Group LLP boosted its stake in Lexicon Pharmaceuticals by 11.1% in the first quarter. Wellington Management Group LLP now owns 279,874 shares of the biopharmaceutical company’s stock worth $4,013,000 after buying an additional 27,964 shares during the period. Teachers Advisors LLC boosted its stake in Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Teachers Advisors LLC now owns 106,890 shares of the biopharmaceutical company’s stock worth $1,478,000 after buying an additional 27,378 shares during the period. Finally, Norges Bank purchased a new stake in Lexicon Pharmaceuticals during the fourth quarter worth $12,582,000.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) opened at 14.62 on Friday. The firm’s 50-day moving average is $16.17 and its 200 day moving average is $15.41. The firm’s market cap is $1.54 billion. Lexicon Pharmaceuticals, Inc. has a 1-year low of $13.41 and a 1-year high of $19.62.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.12. The business had revenue of $12 million for the quarter, compared to the consensus estimate of $18.34 million. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The firm’s quarterly revenue was down 40.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.37) EPS. On average, equities analysts forecast that Lexicon Pharmaceuticals, Inc. will post ($1.45) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.dailypolitical.com/2017/08/13/c-worldwide-group-holding-a-s-has-178000-stake-in-lexicon-pharmaceuticals-inc-lxrx.html.

A number of analysts recently weighed in on LXRX shares. BidaskClub cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. ValuEngine raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. HC Wainwright set a $27.00 target price on shares of Lexicon Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 3rd. Finally, Wedbush reissued an “ourperform” rating and set a $39.00 target price on shares of Lexicon Pharmaceuticals in a research note on Monday, August 7th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $27.00.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.